Rounds / Orizuru Therapeutics
Orizuru Therapeutics raises ¥300M (Additional investment)
Kyoto University spin-out developing iPS-cell-derived pancreatic islet (OZTx-410) and cardiomyocyte (OZTx-556) products.
- Company
- Orizuru Therapeutics
- Reported
- 7 Aug 2026 · that week's brief
- Stage
- Additional investment · 「追加投資」 · Other
- Amount
- ¥300M1 · as announced: 「約3億円（追加出資）」
- Breakdown
- Equity ¥300M
- Registry
- Not checked against the registry yet
- Notes
- Announced by the investor (KYOTO-iCAP Fund 2) on 7 Aug 2026; the company has not announced it. FY3/2026 gazette accounts: net loss ¥2.27B, total assets ¥1.07B.
- Investors
- Kyoto University Innovation Capital
- Sector
- BiotechDeep tech
- Source
- Release (Kyoto iCAP (investor release); no announcement found on the company's own site yet)
1 ≈ ~$1.9M at the ECB reference rate on 2026-08-07 (¥1 = $0.00632). Yen is the figure of record. Methodology
Get the weekly brief
Every Japanese funding round worth knowing, in one English email. Free. Subscribe on Substack →
Every Japanese funding round worth knowing, in one English email. Free. Subscribe on Substack →